162 related articles for article (PubMed ID: 32790196)
1. Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT Study.
Ramchand SK; David NL; Lee H; Bruce M; Bouxsein ML; Leder BZ; Tsai JN
J Bone Miner Res; 2021 Jan; 36(1):41-51. PubMed ID: 32790196
[TBL] [Abstract][Full Text] [Related]
2. Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study.
Tsai JN; Nishiyama KK; Lin D; Yuan A; Lee H; Bouxsein ML; Leder BZ
J Bone Miner Res; 2017 Oct; 32(10):2001-2009. PubMed ID: 28608571
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension.
Ramchand SK; David NL; Lee H; Bruce M; Bouxsein ML; Tsai JN; Leder BZ
J Bone Miner Res; 2023 Jan; 38(1):26-34. PubMed ID: 36333954
[TBL] [Abstract][Full Text] [Related]
4. Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT.
Agarwal S; Shiau S; Kamanda-Kosseh M; Bucovsky M; Kil N; Lappe JM; Stubby J; Recker RR; Guo XE; Shane E; Cohen A
J Bone Miner Res; 2023 Jan; 38(1):35-47. PubMed ID: 36335582
[TBL] [Abstract][Full Text] [Related]
5. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.
Tsai JN; Uihlein AV; Burnett-Bowie SA; Neer RM; Zhu Y; Derrico N; Lee H; Bouxsein ML; Leder BZ
J Bone Miner Res; 2015 Jan; 30(1):39-45. PubMed ID: 25043459
[TBL] [Abstract][Full Text] [Related]
6. Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study).
Tsai JN; Uihlein AV; Burnett-Bowie SM; Neer RM; Derrico NP; Lee H; Bouxsein ML; Leder BZ
J Clin Endocrinol Metab; 2016 May; 101(5):2023-30. PubMed ID: 26964731
[TBL] [Abstract][Full Text] [Related]
7. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Macdonald HM; Nishiyama KK; Hanley DA; Boyd SK
Osteoporos Int; 2011 Jan; 22(1):357-62. PubMed ID: 20458576
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension.
Ramchand SK; David NL; Lee H; Eastell R; Tsai JN; Leder BZ
J Bone Miner Res; 2021 May; 36(5):921-930. PubMed ID: 33507574
[TBL] [Abstract][Full Text] [Related]
9. Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study.
Nishiyama KK; Cohen A; Young P; Wang J; Lappe JM; Guo XE; Dempster DW; Recker RR; Shane E
J Clin Endocrinol Metab; 2014 Jul; 99(7):2418-25. PubMed ID: 24684466
[TBL] [Abstract][Full Text] [Related]
10. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.
Tsai JN; Lee H; David NL; Eastell R; Leder BZ
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):767-775. PubMed ID: 31447409
[TBL] [Abstract][Full Text] [Related]
11. Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT.
Ramchand SK; David NL; Leder BZ; Tsai JN
J Clin Endocrinol Metab; 2020 Mar; 105(3):890-7. PubMed ID: 31674641
[TBL] [Abstract][Full Text] [Related]
12. Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment.
Geusens P; Bevers MS; van Rietbergen B; Messina OD; Lespessailles E; Oliveri B; Chapurlat R; Engelke K; Chines A; Huang S; Saag KG; van den Bergh JP
J Bone Miner Res; 2022 Jun; 37(6):1136-1146. PubMed ID: 35340062
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.
Chiba K; Okazaki N; Kurogi A; Watanabe T; Mori A; Suzuki N; Adachi K; Era M; Yokota K; Inoue T; Yabe Y; Furukawa K; Kondo C; Tsuda K; Ota S; Isobe Y; Miyazaki S; Morimoto S; Sato S; Nakashima S; Tashiro S; Yonekura A; Tomita M; Osaki M
Bone; 2022 Jul; 160():116416. PubMed ID: 35398293
[TBL] [Abstract][Full Text] [Related]
14. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
Burghardt AJ; Kazakia GJ; Sode M; de Papp AE; Link TM; Majumdar S
J Bone Miner Res; 2010 Dec; 25(12):2558-71. PubMed ID: 20564242
[TBL] [Abstract][Full Text] [Related]
15. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength.
Cheung AM; Majumdar S; Brixen K; Chapurlat R; Fuerst T; Engelke K; Dardzinski B; Cabal A; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Bone Miner Res; 2014 Aug; 29(8):1786-94. PubMed ID: 24643905
[TBL] [Abstract][Full Text] [Related]
16. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Effects of Teriparatide Treatment on Bone Mineral Density, Bone Microarchitecture, and Bone Strength.
Kleerekoper M; Greenspan SL; Lewiecki EM; Miller PD; Kendler DL; Maricic M; Keaveny TM; Kopperdahl DL; Ruff VA; Wan X; Janos B; Krohn K
J Bone Joint Surg Am; 2014 Jun; 96(11):e90. PubMed ID: 24897747
[TBL] [Abstract][Full Text] [Related]
18. Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients.
Bonani M; Meyer U; Frey D; Graf N; Bischoff-Ferrari HA; Wüthrich RP
Kidney Blood Press Res; 2016; 41(5):614-622. PubMed ID: 27622692
[TBL] [Abstract][Full Text] [Related]
19. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
20. The effect of denosumab and alendronate on trabecular plate and rod microstructure at the distal tibia and radius: A post-hoc HR-pQCT study.
Hu YJ; Chines A; Shi Y; Seeman E; Guo XE
Bone; 2022 Jan; 154():116187. PubMed ID: 34530172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
